Healthy Skepticism Library item: 8678
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Koren G, MacLeod S, Davis D.
Drugs in pregnancy: acknowledging challenges--finding solutions.
Can J Clin Pharmacol 2007 Win; 14:(1):e2-4
http://www.cjcp.ca/pdf/CJCP2007_e2_e4.pdf
Abstract:
Due to obvious ethical issues of experimenting drugs during fetal development, women and their unborn babies are commonly excluded from drug trials. As a result, these two groups of patients are commonly orphaned from the revolution in drug therapy witnessed in the last generation.
The removal of Bendectin from the American market despite being safe in pregnancy sent a chilling signal to drug companies, essentially discouraging them from developing or studying drugs for pregnant patients. Even in areas which are exclusively typical of pregnancy (e.g.., morning sickness or tocolysis) no new drug trials are performed. Consequently, the advance in therapeutics in pregnancy lags substantially behind the same conditions or drugs in nonpregnant women, or men…
Keywords:
MeSH Terms:
Abnormalities, Drug-Induced/prevention & control*
Antidepressive Agents/adverse effects
Antidepressive Agents/therapeutic use
Canada
Clinical Trials*
Drug Industry/standards
Drug Industry/trends
Drug Toxicity
Female
Fetal Development/drug effects
Glyburide/adverse effects
Glyburide/therapeutic use
Humans
Patient Selection
Pharmaceutical Preparations/adverse effects*
Pregnancy
Pregnancy Complications/drug therapy*
Pregnancy Complications/prevention & control
Pregnancy Trimesters
Substances:
Antidepressive Agents
Pharmaceutical Preparations
Glyburide
Notes:
Free full text
